Amid record ETF inflows, niche funds like BBC, LATR, and FMED offer targeted exposure to biotech trials, buy-now-pay-later firms, and disruptive medicine, with notable recent returns.
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according...
Last year’s projected healthcare spending growth rate of 7.5% outpaced GDP growth for the first time since the pandemic. As an aging population creates more demand for medical care, it opens up opportunities...